Neurochem Inc.
Laval, QC
Company Overview
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The Company's pipeline of proprietary, disease-modifying oral products addresses critical unmet medical needs. Fibrillex, designated as an orphan drug and as a Fast Track Product candidate, is also part of a Continuous Marketing Applications Pilot 2 program and has completed a Phase II/III clinical trial for the treatment of AA Amyloidosis. The Company expects to issue the quality-controlled trial data during the second quarter of 2005. Alzhemed, for the treatment of Alzheimer's Disease, is in a Phase III clinical trial and Cerebril, for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase II clinical trial.
Neurochem's most advanced drug candidates focus on the treatment of certain amyloidosis and neurological diseases. Its most advanced drug candidate is Fibrillex, for the treatment of AA Amyloidosis, a disease associated with chronic infectious or inflammatory diseases including rheumatoid arthritis and Crohn's disease.
Neurochem's second most advanced product candidate is Alzhemed, for the treatment of AD. The company has launched a phase III clinical trial in North America in mild-to-moderate AD patients and is currently advancing an open-label phase II extension study.
Neurochem's third most advanced product candidate is Cerebril, for the treatment of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy. The company has completed a phase II clinical trial.
In addition, to the advanced programs in clinical development, Neurochem has a program for the treatment or recurrent seizures induced by Traumatic Brain Injury.
Moreover, it has research and development activities focused on other aspects of neurological diseases, with a strong focus on developing a multi-pronged approach to the prevention and treatment of AD at different stages of development. Neurochem is also committed to advancing its technology towards the discovery of therapeutics for the prevention and treatment of the disease.
Neurochem has obtained from the Food and Drug Administration (U. S. A.) the 'Orphan Drug' status and the 'Orphan Medicinal Product' designation in Europe for Fibrillex towards the treatment of AA Amyloidosis. FDA has granted Fast Track Product Designation for Fibrillex. Fibrillex has been selected by the Cardio-Renal Drug Product Division of the US Food and Drug Administration (FDA) to be part of the Continuous Marketing Applications Pilot 2 program aimed at further accelerating the development and eventual marketing of this product candidate. Under this Pilot 2 program, each FDA division is permitted to select only one product candidate.
Neurochem has also established a number of strategic alliances to support its synthetic vaccine program for Alzheimer's Disease. These include a strategic alliance with the National Research Council of Canada's Institute for Biological Sciences, as well as an in-licensing agreement with PRAECIS PHARMACEUTICALS INCORPORATED.
At present, the Company employs 160 people and is located in Laval, Qubec, Canada (www. neurochem. com).
Company Information
Physical Address
275 Armand-Frappier Blvd
Laval, QC H7V 4A7
CA
Mailing Address
275 Armand-Frappier Blvd
Laval, QC H7V 4A7
CA
Additional Details
Legal Name: Neurochem Inc.
Number of Employees: 160
CA
Neurochem's core technology platform resides largely in the ability to design and synthesize small organic molecules that mimic the sulfated GAG molecules. Capitalizing on the key role of GAGs in the processes of amyloid fibril formation and deposition, Neurochem has designed and patented small organic molecules (product candidates) for the binding of the fibrillogenic protein to the cells. In so doing, the therapeutic molecules inhibit the process of fibrillogenesis.
The Company refers to these product candidates as 'GAG mimetics'. Neurochem believes that this approach represents novel and effective therapeutic agents for many of the 20 amyloid-related diseases known to this day including Alzheimer's Disease, AA Amyloidosis, Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy and others.
Neurochem: a leading international authority in amyloid disorders including Alzheimer's Disease.
First company to have advanced to a phase II/III anti-amyloid trial in the world.
First company to have advanced to a phase II/III anti-amyloid trial in the world.
Prestigious Awards: 'Prix de l'Emergence 2001 ('La Fondation Armand-Frappier), 'Genesis Award 2001' (BIOQubec)
160, 000 sq feet
Contacts
Lise Hbert
Title: Vice President Corporate Communications
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Andreas Orfanos
Title: Executive Vice President, Strategic Plan
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Philippe Calais
Title: President
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Francesco Bellini
Title: Chairman and CEO
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Francine Gervais
Title: Vice President, Research & Development
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Denis Garceau
Title: Vice President, Drug Development
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Claude Michaud
Title: Senior Vice President, Finance and CFO
Area of Responsibility: Management Executive, Finance/Accounting
Phone: Show phone
Fax: Show fax
Email: Show email
Christinne Lennon
Title: Vice President, Business Development
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Judith Paquin
Title: Vice President, Human Resources
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
David Skinner
Title: General Counsel and Corporate Secretary
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Products
-
Biotechnology
PRODUCTS UNDER DEVELOPMENT / Fibrillex: Neurochems lead investigational product candidate for the treament of AA Amyloidosis has completed a Phase II/III clinical trial in 2004 and has received Orphan Drug Designation (ODD) in the USA and the Orphan Medicinal Product (OMP) in Europe. / Alzhemed: Neurochems lead investigational product candidate for the treatment of Alzheimers Disease, is in Phase III clinical trial in 2004 / Cerebril: Neurochems lead investigational product candidate for the treatment of Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy (CAA), has completed a Phase II clinical trial in the U. S.
- Pharmaceutical Products
NAICS Categories
- 325410 Pharmaceutical and Medicine Manufacturing
- 541710 Research and Development in the Physical, Engineering and Life Sciences
Additional Information
541710, 325410